← Eichor
Study identifier: NCT06578234 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

Condition: Chronic Coronary Syndrome · Coronary Artery Disease · Ischemic Heart Disease  ·  Sponsor: Region Skane

PhasePhase 4
Planned participants180
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersYes

About this study

Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram/kg/min) to the high dose of adenosine (210 microgram/kg/min) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.

This description comes directly from the study's public registry record.

Talk to the study team

Henrik Engblom, MD, PhD  ·  046171000  ·  henrik.engblom@med.lu.se

Always discuss trial participation with your own doctor first.

Locations (1)

Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University HospitalLund, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06578234